Van Cleef Asset Management Inc Reduces Position in Eli Lilly and Company $LLY

Van Cleef Asset Management Inc decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,786 shares of the company’s stock after selling 610 shares during the quarter. Van Cleef Asset Management Inc’s holdings in Eli Lilly and Company were worth $2,172,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Disciplined Investors L.L.C. grew its position in Eli Lilly and Company by 15.7% in the 2nd quarter. Disciplined Investors L.L.C. now owns 339 shares of the company’s stock valued at $264,000 after acquiring an additional 46 shares during the last quarter. Bensler LLC lifted its position in shares of Eli Lilly and Company by 5.5% during the second quarter. Bensler LLC now owns 17,927 shares of the company’s stock worth $13,974,000 after purchasing an additional 934 shares during the last quarter. AE Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 8.9% during the second quarter. AE Wealth Management LLC now owns 68,235 shares of the company’s stock valued at $53,193,000 after purchasing an additional 5,592 shares during the period. Stokes Family Office LLC boosted its stake in shares of Eli Lilly and Company by 2.3% during the second quarter. Stokes Family Office LLC now owns 4,208 shares of the company’s stock valued at $3,280,000 after purchasing an additional 96 shares during the period. Finally, Paradigm Asset Management Co. LLC grew its holdings in shares of Eli Lilly and Company by 200.0% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,050 shares of the company’s stock worth $819,000 after purchasing an additional 700 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 4,314 shares of company stock worth $2,766,929 in the last three months. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $923.35 on Friday. The firm has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company’s 50 day moving average is $799.97 and its 200 day moving average is $775.76. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LLY shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Guggenheim reaffirmed a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. BMO Capital Markets boosted their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $960.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.